Psychiatric Pharmacogenomics:  Application of Novel Approaches Leads to New Insights

Joanna Biernacka, Ph.D.

Introduction

Dr. Biernacka's research is focused on the genetics and pharmacogenomics of complex neuropsychiatric diseases included bipolar disorder, addiction, and other neuropsychiatric traits.  Dr. Biernacka obtained a Ph.D. in Biostatistics from the University of Toronto in 2005, with an emphasis on statistical genetics, and then spent two years as a postdorctoral research fellow, including one year at Cambridge University and one year at Newcastle University.  In 2007, Dr. Biernacka joined Mayo Clinic's faculty as the lead statistical geneticist and one of the 5 scholars in the S.C. Johnson Program in the Genomics of Addiction.  Since that time, she has dedicated her effort to research in psychiatry and neurology, expanding her role to several of Mayo's growing neuropsychiatric genetics resarch initiatives.  She now serves as Co-Principal Investigator for Mayo's Bipolar Disorder Biobank and Biomarker Development Program and as Director of the Psychiatric Genomics and Pharmacogenomics Research Program.  Her recent work emphasizes the heterogeneity of complex pschiatric traits, and underscores the importance of accounting for this heterogeneity in efforts to identify genetic factors contributing to these traits. 

Learning Objectives

1. Review the current state of knowledge in psychiatric pharmacogenomics spanning mood and alcohol use disorders.

2. Recognize the value and limitations of genome-wide association studies in identifying genetic predictors of drug response in psychiatric illness.

3. Describe the application of novel analytical approaches in psychiatric pharmacogenomics studies.

Live webcast available at: http://videos.mayo.edu/live
1 AMA PRA Category 1 Credit(s)™ hour is offered for watching this Webcast live. Ethos will be implemented for all post presentation surveys. To document your attendance, please text the code given at the presentation to 507-200-3010. For questions, email rstpsychgr@mayo.edu.

Accreditation Statement

In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s)

AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

APA
The Department of Psychiatry and Psychology at Mayo Clinic, Rochester, is approved by the American Psychological Association to sponsor continuing education credits for psychologists. The Department of Psychiatry and Psychology at Mayo Clinic, Rochester maintains responsibility for this program and its content.

Archived webcast available at: Psychiatry & Psychology Video Library

Industry Acknowledgment (if applicable): None.

All participants MUST complete the evaluation in order to get CME or APA Credit.

1) Text the CODE announced at the session within 48 hours to (507) 200-3010
2) Login at ce.mayo.edu and go to My Account, My Courses, Registered Courses, click Session title and START to access the required Evaluation.
-or-
Click the START button on that session page.
3) Evaluation must be completed within 2 weeks.

Disclosure Summary
As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.
 

Listed below are individuals with control of the content of this program who have disclosed…

Relevant financial relationship(s) with industry:

Mark Frye, M.D. - Mayo Clinic

Grant Support: AssureRx, Janssen R&D, Myriad, Pfizer Consultant: Janssen R&D, Mitsubishi Tanabe Pharma Corp., Myriad Genetics, Sunovion, Supernus Pharmaceuticals, Teva Pharmaceuticals, Neuralstem, Inc.

CME/Travel: American Physician Institute, CME Outfitters

No relevant financial relationship(s) with industry:
Kriti Gandhi, M.D., Allison Holgerson, Ph.D., Matej Markota, M.D., Charlene Nelson, Reem Shafi, M.B.B.S., Larua Suarez, M.D.

Speaker:  Joanna Biernacka, Ph.D.

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:

NONE